Print Friendly, PDF & Email


Catalogue number: X1869B

Product Type Blocking Peptide
Units50 µg
Application Antibody function blocking

The expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) is associated with acquired paclitaxel (Taxol) resistance, and is expressed in a variety of cancers - e.g., breast cancer, leukemia, and melanoma. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40) and 8226/MDR(10)V. Weakly expressed in kidney. TRAG-3 is an attractive target for immunotherapy of cancer. First identified as a novel cancer/testis antigen, TRAG-3, (Taxol Resistance Associated Gene-3) was initially discovered in a search for new genes involved in drug resistance. Early studies of TRAG-3 revealed a minimal to absent expression in normal tissues and a marked over-expression in many carcinoma cell lines including several melanoma lines. By RT-PCR evaluation of TRAG-3 two transcripts are seen in many carcinoma cell lines with products in the the 799 bp and a second alternatively spliced transcript.

Synonyms: Taxol resistance-associated gene-3


Product Form: Unconjugated

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Concentration: See vial for concentration

Blocking peptide for use with Trag-3 antibodies (Cat. Nos. X1871P & X1872P).

Functional Analysis: Antibody Function Blocking

Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Product Stability: Products are stable for one year from purchase when stored properly

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

Safety Datasheet(s) for this product:
Sodium Azide




Contact us

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464
Phone: 978-425-1370